Ads
related to: faricimab phase 1 treatment- Dosing & Administration
View Dosing Information
& Administration Options.
- About Biosimilars
Review Important Info. View
Full Prescribing & Safety Info
- About PAVBLU™
HCPs - Get More Information At The
Official Website.
- Dosing Information
Find PAVBLU™ Dosing And
Administration Info.
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
One phase II trial evaluated faricimab's efficacy and safety in comparison to ranibizumab and showed clinically meaningful and statistically significant improvements in visual acuity. [ 12 ] [ 20 ] Two phase III multi-center randomized studies were completed on 1,891 diabetic participants with diabetic macular edema (DME).
[1] [2] Anti-α-synuclein drugs are under development for treatment of Parkinson's disease and other α-synuclein-related diseases. [1] [2] Examples include the monoclonal antibodies prasinezumab and cinpanemab, which both failed to show effectiveness in slowing the progression of Parkinson's disease in phase 2 clinical trials. [1]
Rinucumab (REGN2176) is a monoclonal antibody designed for the treatment of neovascular age-related macular degeneration. [ 1 ] [ 2 ] This drug was developed by Regeneron Pharmaceuticals, Inc.
146 796.63 g·mol −1 ... Icrucumab (IMC-18F1) is a human monoclonal antibody designed for the treatment of solid tumors. [1] [2] ... It is undergoing Phase I trials ...
Solanezumab was tested in two phase 3 clinical trials, EXPEDITION 1 and 2 (NCT00905372 and NCT00904683). Both were randomized, double-blind and placebo-controlled. Patients with mild-to-moderate Alzheimer's disease received either placebo or 400 mg solanezumab infusions every 4 weeks over 18 months.
Bapineuzumab (nicknamed "bapi") [1] is a humanized monoclonal antibody that acts on the nervous system and may have potential therapeutic value for the treatment of Alzheimer's disease and possibly glaucoma. [2]
Ad
related to: faricimab phase 1 treatment